FDA Proposes Reclassifying Blue Light Cystoscopy Systems from Class III to Class II — Photocure ASA

Event summary

The FDA proposed reclassifying cystoscopic systems for bladder cancer detection from Class III to Class II on August 14, 2026.
The move follows a review of scientific, clinical, and post-market evidence by the FDA.
Photocure's Cysview is an FDA-approved optical imaging agent used in blue light cystoscopy (BLC).
The reclassification aims to establish special controls for these devices under the 510(k) pathway.

The big picture

The FDA's proposal to reclassify cystoscopic systems reflects a broader trend toward streamlining regulatory pathways for well-established medical technologies. This move could accelerate innovation and adoption of blue light cystoscopy, potentially lowering costs and improving outcomes for bladder cancer patients. Photocure stands to benefit from expanded access and increased usage of its Cysview imaging agent.

What we're watching

Regulatory Approval Timeline: The pace at which the FDA finalizes the reclassification will determine how quickly Photocure can expand BLC access in the U.S.
Market Expansion Potential: Whether the proposed transition to Class II will support greater innovation and broaden the availability of BLC in the United States.
Competitive Dynamics: How this regulatory shift might influence other companies developing similar diagnostic technologies for bladder cancer.